ArticleAMB Express2025
Agarwood essential oils alleviate hypoxia-induced gastric and small intestinal injury.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Agarwood, a traditional Chinese medicine, has been widely used in the treatment of gastrointestinal diseases. The antibacterial and antioxidant properties of agarwood essential oils (EOs) have been well documented. High-altitude (> 2500 m) regions attract tens of millions of visitors worldwide each year; however, the hypoxic environment poses a threat to the health of the body's organ systems, including the digestive system. Additionally, hypoxia has been reported to alter the gut microbiota and metabolites. Our previous study demonstrated that hypoxia exposure triggered ferroptosis in the gastric and small intestinal mucosa. This study aimed to explore the therapeutic effects and potential mechanisms of EOs in hypoxia-induced gastric and small intestinal mucosal injury. EO effects were evaluated based on clinical manifestations, histopathological assessments, and lipid peroxidation as determined by reactive oxygen species (ROS) and 4-hydroxynonenal (4-HNE) levels. We also assessed microbiota changes through 16 S rRNA gene amplicon sequencing and analyzed metabolites using untargeted liquid chromatography-mass spectrometry in the gastric and small intestinal contents of mice. EO treatment significantly alleviated hypoxia-triggered mucosal damage in the stomach and small intestine. Notably, EOs reduced hypoxia-induced lipid peroxidation and partially recovered the microbiota and metabolite disruptions induced by hypoxia. Specifically, Candidatus_Saccharimonas and Akkermansia may contribute to mucosal repair via regulating xanthoxic acid and aspartylglycosamine, and guanosine, respectively. EOs may provide a promising approach for treating hypoxia-induced gastric and small intestinal damage by repressing lipid peroxidation and regulating the microbiota and metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.